In Jan, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA.

The application market of methyl salicylate is broad, and the data shows that the domestic sales of methyl salicylate preparations exceed 100 million yuan in 2022.

Jiudian Pharmaceutical have many kinds of Antipyretic, Analgesic and Anti – inflammatory Drugs on the market, the successful approval of methyl salicylate API will help the company to open up a broader market space.

   Sodium sulfate adds to the company's line of digestive and metabolic drugs. In addition APIs sodium citrate and potassium citrate, pharmaceutical excipients N, n-dimethylacetamide, n-heptane, butanone, have also obtained registration numbers from CDE recently.

N, n-dimethylacetamide, n-heptane, butanone are commonly used solvents for topical preparations, and Jiudian is the first enterprise to produce and register these three varieties in China.

The annual demand for N, N-dimethylacetamide in China is more than 13,000 tons, and increased year by year. N-heptane is one of the widely used hydrocarbon solvents in industry, there is no domestic manufacturer, and there is only one import Registration Company at present. Butanone is a common high purity solvent, its application prospects are very broad, mainly used in oil refining, adhesives, paint fuel, medicine, chemical industry and other industries.

    Jiudian launch new products every year on the market which guarantees the development of company.